Jade Biosciences, Inc. SEC filings JBIO

Jade Biosciences, Inc. has 509 filings in SEC EDGAR's recent list, going back to Jan 8, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.

Jade Biosciences, Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G Ownership over 5% (passive) Oct 28, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Oct 27, 2026 —
8-K Current report
Other events
Sep 30, 2026 Sep 30, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
10-Q Quarterly report Aug 10, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 10, 2026 Aug 10, 2026
SCHEDULE 13G Ownership over 5% (passive) Jul 17, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 8, 2026 —
8-K Current report
Material agreement
Jul 1, 2026 Jun 29, 2026
4 Insider transaction Jun 26, 2026 Jun 25, 2026
3 Initial insider ownership Jun 26, 2026 Jun 25, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Jun 26, 2026 Jun 25, 2026
4 Insider transaction Jun 11, 2026 Jun 9, 2026
4 Insider transaction Jun 11, 2026 Jun 9, 2026
4 Insider transaction Jun 11, 2026 Jun 9, 2026
4 Insider transaction Jun 11, 2026 Jun 9, 2026
4 Insider transaction Jun 11, 2026 Jun 9, 2026
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Jun 11, 2026 Jun 8, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Jun 9, 2026 —
DEFA14A Additional proxy material Jun 5, 2026 —
8-K Current report
Other events
Jun 4, 2026 Jun 3, 2026
424B5 Prospectus supplement Jun 4, 2026 —
424B5 Prospectus supplement Jun 3, 2026 —
8-K Current report
Regulation FD disclosure, Other events
Jun 1, 2026 Jun 1, 2026
EFFECT Filing May 15, 2026 —
EFFECT Filing May 15, 2026 —
424B3 Prospectus May 15, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
CORRESP Letter to the SEC May 13, 2026 —
CORRESP Letter to the SEC May 13, 2026 —
UPLOAD Letter from the SEC May 13, 2026 —
UPLOAD Letter from the SEC May 13, 2026 —
S-8 Employee stock plan registration May 7, 2026 —
S-3 Shelf registration May 7, 2026 —
S-3 Shelf registration May 7, 2026 —
424B3 Prospectus May 7, 2026 —
424B3 Prospectus May 7, 2026 —
10-Q Quarterly report May 7, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 9, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 27, 2026 —
8-K Current report
Officer or director change
Apr 22, 2026 Apr 18, 2026
PRE 14A Preliminary proxy statement Apr 17, 2026 Jun 9, 2026
8-K Current report
Officer or director change
Apr 2, 2026 Mar 31, 2026
S-8 Employee stock plan registration Mar 6, 2026 —
POS EX Filing Mar 6, 2026 —
POS EX Filing Mar 6, 2026 —
424B3 Prospectus Mar 6, 2026 —
424B3 Prospectus Mar 6, 2026 —
10-K Annual report Mar 6, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 6, 2026 Mar 6, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Mar 5, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 17, 2026 —
4 Insider transaction Feb 13, 2026 Feb 12, 2026
4 Insider transaction Feb 13, 2026 Feb 12, 2026
4 Insider transaction Feb 13, 2026 Feb 12, 2026
4 Insider transaction Feb 13, 2026 Feb 12, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 13, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jan 30, 2026 —
8-K Current report
Results of operations, Regulation FD disclosure
Jan 5, 2026 Jan 5, 2026
EFFECT Filing Dec 30, 2025 —
424B3 Prospectus Dec 30, 2025 —
CORRESP Letter to the SEC Dec 23, 2025 —
UPLOAD Letter from the SEC Dec 23, 2025 —
S-1 Registration statement Dec 22, 2025 —
EFFECT Filing Dec 19, 2025 —
424B3 Prospectus Dec 19, 2025 —
CORRESP Letter to the SEC Dec 17, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Dec 15, 2025 Dec 13, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
S-1 Registration statement Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
10-Q Quarterly report Nov 14, 2025 Sep 30, 2025
8-K Current report
Results of operations, Other events
Nov 14, 2025 Nov 13, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 17, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Oct 16, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Oct 8, 2025 —
4 Insider transaction Oct 8, 2025 Oct 6, 2025
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Oct 7, 2025 Oct 3, 2025
8-K Current report
Officer or director change
Sep 9, 2025 Sep 5, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
8-A12B/A Filing Aug 13, 2025 —
10-Q Quarterly report Aug 13, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 13, 2025 Aug 13, 2025
SCHEDULE 13G Ownership over 5% (passive) Jul 29, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jul 17, 2025 —
4 Insider transaction Jul 14, 2025 Jul 14, 2025
3 Initial insider ownership Jul 14, 2025 Jul 14, 2025
8-K Current report
Material agreement, Officer or director change, Regulation FD disclosure
Jul 1, 2025 Jun 25, 2025
S-8 Employee stock plan registration Jun 30, 2025 —
144 Notice of proposed sale Jun 25, 2025 —
144 Notice of proposed sale Jun 25, 2025 —
144 Notice of proposed sale Jun 24, 2025 —
144 Notice of proposed sale Jun 24, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jun 20, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jun 6, 2025 —
4 Insider transaction May 19, 2025 May 16, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2025 —
8-K Current report
Acquisition or sale of assets, Results of operations, Regulation FD disclosure
May 14, 2025 May 14, 2025
144 Notice of proposed sale May 6, 2025 —
144 Notice of proposed sale May 6, 2025 —
SCHEDULE 13G Ownership over 5% (passive) May 5, 2025 —
SCHEDULE 13G Ownership over 5% (passive) May 5, 2025 —
SCHEDULE 13D Ownership over 5% (active) May 1, 2025 —
4 Insider transaction May 1, 2025 Apr 29, 2025
4 Insider transaction May 1, 2025 Apr 29, 2025
4 Insider transaction May 1, 2025 Apr 29, 2025
4 Insider transaction May 1, 2025 Apr 29, 2025
4 Insider transaction May 1, 2025 Apr 29, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
3 Initial insider ownership May 1, 2025 Apr 28, 2025
8-K Current report
Material agreement, Acquisition or sale of assets, Results of operations, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
May 1, 2025 Apr 28, 2025
4 Insider transaction Apr 30, 2025 Apr 28, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Apr 30, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Apr 30, 2025 —
8-K Current report
Regulation FD disclosure
Apr 29, 2025 Apr 29, 2025
10-Q Quarterly report Apr 25, 2025 Mar 31, 2025
8-K Current report
Other events
Apr 23, 2025 Apr 23, 2025
8-K Current report
Shareholder vote results, Regulation FD disclosure, Other events
Apr 21, 2025 Apr 16, 2025
425 Filing Apr 9, 2025 —
425 Filing Apr 9, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Apr 9, 2025 Apr 9, 2025
425 Filing Apr 9, 2025 —
8-K Current report
Other events
Apr 9, 2025 Apr 9, 2025
425 Filing Apr 7, 2025 —
425 Filing Apr 7, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Apr 7, 2025 Apr 7, 2025
10-K Annual report Mar 27, 2025 Dec 31, 2024
425 Filing Mar 26, 2025 —
SEC STAFF LETTER Filing Mar 25, 2025 —
EFFECT Filing Mar 25, 2025 —
ARS Annual report to shareholders Mar 25, 2025 Dec 31, 2024
424B3 Prospectus Mar 25, 2025 —
CORRESP Letter to the SEC Mar 24, 2025 —
CORRESP Letter to the SEC Mar 24, 2025 —
CORRESP Letter to the SEC Mar 24, 2025 —
S-4/A Filing Mar 24, 2025 —
UPLOAD Letter from the SEC Mar 21, 2025 —
CORRESP Letter to the SEC Mar 14, 2025 —
S-4/A Filing Mar 14, 2025 —
UPLOAD Letter from the SEC Mar 11, 2025 —
425 Filing Mar 3, 2025 —
CORRESP Letter to the SEC Feb 24, 2025 —
S-4/A Form s-4/a Feb 24, 2025 —
SEC STAFF LETTER Filing Feb 18, 2025 —
UPLOAD Letter from the SEC Feb 18, 2025 —
425 Filing Feb 10, 2025 —
425 Filing Feb 4, 2025 —
425 Filing Jan 24, 2025 —
S-4/A Form s-4/a Jan 22, 2025 —
425 Filing Jan 13, 2025 —
S-4 Registration for a merger or exchange Dec 3, 2024 —
RW Filing Nov 25, 2024 —
425 Filing Nov 18, 2024 —
SC 13G/A Amended ownership over 5% (passive) Nov 14, 2024 —
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
425 Filing Oct 31, 2024 —
425 Filing Oct 31, 2024 —
425 Filing Oct 31, 2024 —
425 Filing Oct 31, 2024 —
425 Filing Oct 31, 2024 —
8-K Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
Oct 31, 2024 Oct 30, 2024
8-K Current report
Listing notice
Oct 17, 2024 Oct 11, 2024
8-K Current report
Officer or director change
Oct 10, 2024 Oct 6, 2024
10-Q Quarterly report Aug 12, 2024 Jun 30, 2024
4 Insider transaction Aug 2, 2024 Jul 31, 2024
8-K Current report
Other events
Jul 8, 2024 Jul 8, 2024
8-K/A Amended current report
Exit or restructuring costs
Jul 1, 2024 Jun 25, 2024
8-K Current report
Exit or restructuring costs
Jun 28, 2024 Jun 25, 2024
SC 13D/A Amended ownership over 5% (active) Jun 20, 2024 —
4 Insider transaction Jun 20, 2024 Jun 17, 2024
8-K Current report
Regulation FD disclosure, Other events
Jun 17, 2024 Jun 17, 2024
4 Insider transaction Jun 14, 2024 Jun 14, 2024
4 Insider transaction Jun 14, 2024 Jun 14, 2024
4 Insider transaction Jun 14, 2024 Jun 13, 2024
144 Notice of proposed sale Jun 14, 2024 —
144 Notice of proposed sale Jun 13, 2024 —
S-3 Shelf registration Jun 10, 2024 —
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
4 Insider transaction Jun 7, 2024 Jun 5, 2024
8-K Current report
Shareholder vote results
Jun 7, 2024 Jun 5, 2024

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
JBIO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
, Emerging growth company
SEC CIK
1798749
Former names
Aerovate Therapeutics, Inc. (until Apr 30, 2025)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.